Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer

What this study is about

Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress. Blood cancer patients are among those most affected in terms of quality of life, facing stem cell transplantation after high-dose chemotherapy, a treatment that is recognized as one of the most stressful of cancer therapy, due to the many adverse effects, including pain, and the uncertainty linked to the fear of graft failure. Hypnosis interventions are proving effective in treating common side effects: nausea, pain, fatigue, anxiety, depressive symptoms and improving overall quality of life, and other interventions, based on virtual reality, have shown promising effects on patients' distress and acute pain. The aim of this study is to evaluate the effects of an intervention program combining hypnosis and virtual reality in assisting myeloma and lymphoma patients during stem cell transplantation, with a view to improving their quality of life during this period. The project aims to assess the validity of the intervention, and to evaluate the effects of the intervention on patients' anxiety, pain and fatigue during transplantation. The validity of the intervention will be measured by a questionnaire assessing the relevance and acceptability of the intervention, expected effects, and practical implementation. Socio-demographic and clinical data will be collected from patients, including axiety, pain, fatigue and quality of life, studied at pre (one week after transplantation) and post (one month after transplantation) intervnention, and at follow-up (three month after transplantation).

Who can join (things the study team will check)

✅ You may be able to join if…

• Being 18 years of age or older
• Suffering from multiple myeloma or lymphoma eligible for transplant
• Understanding French

🚫 You may not be able to join if…

• Deafness
• Blindness
• Confusion or psychopathological disorders (for example, schizophrenia) that may impair communication

Where this trial is running

• Centre de Recherche de l'Hôpital Maissonneuve-Rosemont, Montreal, Quebec, Canada

Who to contact

David Ogez, Ph.D · 514-609-4391 · david.ogez@umontreal.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06817759.